ENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
April 04 2019 - 8:31AM
Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage
immunotherapy company, today announced that company management will
make a corporate presentation at the H.C. Wainwright Global Life
Sciences 2019 conference being held at the Grosvenor House in
London, U.K. The presentation is scheduled for April 8, 2019 at
9:10am London Time.
ALLOCETRATM by Enlivex was designed to provide a novel
immunotherapy mechanism of action that targets
life-threatening clinical indications that are defined as “unmet
medical needs”, including prevention or treatment of
complications associated with bone marrow transplantations (BMT)
and/or hematopoietic stem cell transplantations (HSCT); organ
dysfunction and acute multiple organ failure associated with
Sepsis; and enablement of an effective treatment of solid tumors
via immune checkpoint rebalancing.
For more information about the H.C. Wainwright Global Life
Sciences 2019 conference, visit www.hcwevents.com
ABOUT ENLIVEX Enlivex is a clinical stage
immunotherapy company, developing an allogeneic drug pipeline for
immune system rebalancing. Immune system rebalancing is critical
for the treatment of life-threatening immune and inflammatory
conditions which involve an out of control immune system (e.g.
Cytokine Release Syndrome) and for which there are no approved
treatments (unmet medical needs), as well as solid tumors
immune-checkpoint rebalancing. For more information, visit
http://www.enlivex.com.
ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics,
Ltd. shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jul 2023 to Jul 2024